SEC Form 4 · accession 0001209191-19-005512
NovoCure Ltd · NVCR
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Gabriel Leung
Director
Period of report
Jan 25, 2019
Accepted (ET)
Jan 28, 2019 · 4:13 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001645113
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Ordinary SharesF1 | Jan 25, 2019 | M | 20,000 | $3.44 | A | 80,000 | D | |
| Ordinary SharesF2 | Jan 25, 2019 | S | 20,000 | $50.00 | D | 60,000 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Options to Buy Ordinary SharesF3 | $3.44 | Jan 25, 2019 | M | 20,000 | D | — | Sep 14, 2021 | Ordinary Shares | 20,000 | 104,743 | D |
Explanation of responses
- F1These shares were acquired pursuant to a Rule 10b5-1 trading plan adopted by Mr. Leung.
- F2These shares were sold pursuant to a Rule 10b5-1 trading plan adopted by Mr. Leung.
- F3Fully vested as of the date hereof.